Association Between Metabolic Syndrome, Obesity, and Cognitive Performances in Individuals With Bipolar Disorders: Cross‐Sectional and Longitudinal Analyses in the FACE ‐ BD Cohort
Year: 2025
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Metabolic syndrome (MetS) has been suggested to be associated with cognitive impairments in bipolar disorder (BD); however, studies are limited by small sample sizes or cross-sectional design. Our objective is to evaluate the cross-sectional and longitudinal associations between MetS and cognitive performances in a large cohort of individuals with BD. METHODS: 1175 individuals with a DSM-IV diagnosis of BD were included from the FACE-BD cohort, assessed with a standardized battery of clinical and neuropsychological tests and followed up with a cognitive retest at 2 years for a subsample (n = 367). A global cognitive index was created by using a Principal Component Analysis. Associations between MetS and cognitive performances at baseline were explored using multiple analyses of covariance and linear mixed models were used for longitudinal data. RESULTS: The prevalence of MetS was 21.5% in this sample. Multivariable analyses identified associations between MetS and poorer cognitive performance in the cross-sectional analysis, independently of age, gender, education level, psychotropic treatments, and comorbidities. Specifically, individuals with MetS showed poorer results (global cognitive index, cognitive flexibility, inhibition, and verbal memory). After adjustment, the longitudinal analysis showed no change in the global cognitive index at year 2 and no time × metabolic syndrome interaction. CONCLUSIONS: Our results suggest that MetS is cross-sectionally, but not longitudinally, associated with poorer cognitive performances in BD. This study highlights the importance of systematically and accurately screening for metabolic abnormalities in individuals with BD, and screening for cognitive deficit especially in individuals with MetS. Our results suggest that MetS is not a risk factor for cognitive decline during the follow-up, but further longitudinal studies are required.
Source: Acta Psychiatrica Scandinavica
DOI: 10.1111/acps.70048
Institutions: Inserm, Université Paris-Est Créteil, Fondation FondaMental, Institut Mondor de Recherche Biomédicale, Université Paris Cité, Hôpital Fernand-Widal, Optimisation Thérapeutique en Neuropsychopharmacologie, Hôpitaux Universitaires Henri-Mondor, Commissariat à l'Énergie Atomique et aux Énergies Alternatives, CEA Paris-Saclay, Centre Hospitalier Charles Perrens, Princess Grace Hospital Centre, Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire de Montpellier, Institut de Génomique Fonctionnelle, Université de Montpellier, Hôpital Louis-Mourier, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Institut de Psychiatrie et Neurosciences de Paris, Centre Hospitalier Universitaire de Besançon, Laboratoire de recherches Intégratives en Neurosciences et psychologie Cognitive, Université de Franche-Comté, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Institut de Neurosciences de la Timone, Institut Pascal, Université Clermont Auvergne, Clermont Auvergne INP, Grenoble Institute of Neurosciences, Université Grenoble Alpes, Imagerie Adaptative Diagnostique et Interventionnelle, Université de Lorraine, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Saclay, Centre de recherche en Epidémiologie et Santé des Populations, Centre Hospitalier de Versailles
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,880
OpenAlex ID: W4416440996